Vytorin Drug Interactions

Niacin
Both niacin and Vytorin alone can increase the chances of developing serious muscle problems. Therefore, combining these medicines may cause an even greater risk. If you are taking both of these products, your healthcare provider may choose to monitor your progress closely and make necessary dosing adjustments (see Niacin and Vytorin).
 
Protease Inhibitors
If you are taking Vytorin and an HIV protease inhibitor, your body may metabolize the medicines differently than intended. This can cause significant reactions, including increasing the risk of developing serious muscle problems, such as myopathy or rhabdomyolysis. Unless your healthcare provider feels that the benefits outweigh the risks, these medicines should not be combined.
 
Nefazodone
If you are taking Vytorin and nefazodone, your body may metabolize the medicines differently than intended. This can cause significant reactions, including increasing the risk of developing serious muscle problems, such as myopathy or rhabdomyolysis. Unless your healthcare provider feels that the benefits outweigh the risks, these medicines should not be taken together.
 
Verapamil
Combining verapamil and Vytorin may cause your body to metabolize the drugs differently than intended. This can cause significant reactions, including increasing the risk of developing serious muscle problems (myopathy or rhabdomyolysis). If you are taking both of these medicines, your healthcare provider may choose to monitor your progress closely and make necessary dosing adjustments. Your Vytorin dosage should not exceed 20 mg.
 
Warfarin
Vytorin may increase the risk of bleeding due to warfarin. When starting or stopping Vytorin therapy and/or changing the dosage, your healthcare provider may choose to monitor your INR and prothrombin time more closely and make any necessary adjustments. Prothrombin time and INR are tests used to measure how well your blood is clotting.
  
(Vytorin Drug Interactions Continued: Page 5)
Pages:

Previous 1 2 3 4 5 Next

Written by/reviewed by: Kristi Monson, PharmD; Arthur Schoenstadt, MD
Last reviewed by: Kristi Monson, PharmD;
Other Articles in This eMedTV Presentation